{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:04:06Z","timestamp":1790892246463,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1038\/s41584-022-00844-x","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T17:03:35Z","timestamp":1663779815000},"page":"619-620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Beyond joint pain, could each gout flare lead to heart attack?"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2862-0442","authenticated-orcid":false,"given":"Hyon K.","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-8348","authenticated-orcid":false,"given":"Natalie","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"844_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41584-021-00725-9","volume":"18","author":"HK Choi","year":"2022","unstructured":"Choi, H. K., McCormick, N. & Yokose, C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat. Rev. Rheumatol. 18, 97\u2013111 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"844_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2022.11390","volume":"328","author":"E Cipolletta","year":"2022","unstructured":"Cipolletta, E. et al. Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA 328, 440\u2013450 (2022).","journal-title":"JAMA"},{"key":"844_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","volume":"73","author":"F Perez-Ruiz","year":"2013","unstructured":"Perez-Ruiz, F. et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann. Rheum. Dis. 73, 177\u2013182 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"844_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/art.41638","volume":"73","author":"HK Choi","year":"2021","unstructured":"Choi, H. K., Neogi, T., Stamp, L. K., Terkeltaub, R. & Dalbeth, N. Reassessing the cardiovascular safety of febuxostat: implications of the Febuxostat versus Allopurinol Streamlined Trial. Arthritis Rheumatol. 73, 721\u2013724 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"844_CR5","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1056\/NEJMoa1702090","volume":"378","author":"JC Kwong","year":"2018","unstructured":"Kwong, J. C., Schwartz, K. L. & Campitelli, M. A. Acute myocardial infarction after laboratory-confirmed influenza infection. N. Engl. J. Med. 378, 2540\u20132541 (2018).","journal-title":"N. Engl. J. Med."},{"key":"844_CR6","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1056\/NEJMoa041747","volume":"351","author":"L Smeeth","year":"2004","unstructured":"Smeeth, L. et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 351, 2611\u20132618 (2004).","journal-title":"N. Engl. J. Med."},{"key":"844_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/BOR.0000000000000779","volume":"33","author":"C Yokose","year":"2021","unstructured":"Yokose, C., McCormick, N. & Choi, H. K. The role of diet in hyperuricemia and gout. Curr. Opin. Rheumatol. 33, 135\u2013144 (2021).","journal-title":"Curr. Opin. Rheumatol."},{"key":"844_CR8","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif, J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497\u20132505 (2019).","journal-title":"N. Engl. J. Med."},{"key":"844_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41584-022-00804-5","volume":"18","author":"HK Choi","year":"2022","unstructured":"Choi, H. K., Zhang, Y. & Dalbeth, N. When underlying biology threatens the randomization principle - initial gout flares of urate-lowering therapy. Nat. Rev. Rheumatol. 18, 543\u2013549 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"844_CR10","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/art.42160","volume":"74","author":"KG Saag","year":"2022","unstructured":"Saag, K. G., Becker, M. A. & White, W. B. Evaluation of the relationship between serum urate levels, clinical manifestations of gout, and death from cardiovascular causes in patients receiving febuxostat or allopurinol in an outcomes trial. Arthritis Rheumatol. 74, 1593\u20131601 (2022).","journal-title":"Arthritis Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00844-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00844-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00844-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T13:09:41Z","timestamp":1666703381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00844-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1038\/s41584-022-00844-x","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"assertion":[{"value":"21 September 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.K.C. declares receipt of research support from Horizon, and consulting fees from Allena, Protalix, and LG Chem. N.M. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}